Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Clinical trial NCT07643623 · RECRUITING
Trial details
- NCT number
- NCT07643623
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-31
- Primary completion
- 2031-12-31
- Enrollment
- 720
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.